Skip to content
Screener

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.39B-13.4%
Gilead Sciences logo
Gilead SciencesGILD
$3.57B+332%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-$14.38M+6.8%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-$20.36M+11.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$60.84M+9.8%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$12.91M+75.6%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$483.93M+261%
Enterprise value$460.9M+433%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219397
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accrued compensation(6,876)(1,804)
Other accrued expenses and current liabilities(4,351)(2,306)
Operating lease liability(503)(963)
Net cash used in operating activities(41,597)(44,915)
Cash flows from investing activities
Purchases of available-for-sale marketable securities(115,901)(81,122)
Proceeds from maturities of available-for-sale marketable securities65,70086,700
Net cash provided by (used in) investing activities(50,201)5,578

Item 1. Financial Statements (unaudited)

FAQ

What is Kyverna Therapeutics, Inc.'s operating cash flow?
Kyverna Therapeutics, Inc. (KYTX) reported operating cash flow of -$41.6M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s operating cash flow changed year-over-year?
Kyverna Therapeutics, Inc.'s operating cash flow increased by 7.4% year-over-year, from -$44.92M to -$41.6M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s operating cash flow?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating cash flow has grown at a 71.3% compound annual growth rate (CAGR), from -$52.41M to -$153.71M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Kyverna Therapeutics, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude